_version_ 1784719815733149696
author Bastian, Lorenz
Hartmann, Alina M.
Beder, Thomas
Hänzelmann, Sonja
Kässens, Jan
Bultmann, Miriam
Hoeppner, Marc P.
Franzenburg, Sören
Wittig, Michael
Franke, Andre
Nagel, Inga
Spielmann, Malte
Reimer, Niklas
Busch, Hauke
Schwartz, Stefan
Steffen, Björn
Viardot, Andreas
Döhner, Konstanze
Kondakci, Mustafa
Wulf, Gerald
Wendelin, Knut
Renzelmann, Andrea
Kiani, Alexander
Trautmann, Heiko
Neumann, Martin
Gökbuget, Nicola
Brüggemann, Monika
Baldus, Claudia D.
author_facet Bastian, Lorenz
Hartmann, Alina M.
Beder, Thomas
Hänzelmann, Sonja
Kässens, Jan
Bultmann, Miriam
Hoeppner, Marc P.
Franzenburg, Sören
Wittig, Michael
Franke, Andre
Nagel, Inga
Spielmann, Malte
Reimer, Niklas
Busch, Hauke
Schwartz, Stefan
Steffen, Björn
Viardot, Andreas
Döhner, Konstanze
Kondakci, Mustafa
Wulf, Gerald
Wendelin, Knut
Renzelmann, Andrea
Kiani, Alexander
Trautmann, Heiko
Neumann, Martin
Gökbuget, Nicola
Brüggemann, Monika
Baldus, Claudia D.
author_sort Bastian, Lorenz
collection PubMed
description
format Online
Article
Text
id pubmed-9162919
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91629192022-06-05 UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment Bastian, Lorenz Hartmann, Alina M. Beder, Thomas Hänzelmann, Sonja Kässens, Jan Bultmann, Miriam Hoeppner, Marc P. Franzenburg, Sören Wittig, Michael Franke, Andre Nagel, Inga Spielmann, Malte Reimer, Niklas Busch, Hauke Schwartz, Stefan Steffen, Björn Viardot, Andreas Döhner, Konstanze Kondakci, Mustafa Wulf, Gerald Wendelin, Knut Renzelmann, Andrea Kiani, Alexander Trautmann, Heiko Neumann, Martin Gökbuget, Nicola Brüggemann, Monika Baldus, Claudia D. Leukemia Letter Nature Publishing Group UK 2022-04-09 2022 /pmc/articles/PMC9162919/ /pubmed/35397658 http://dx.doi.org/10.1038/s41375-022-01557-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Letter
Bastian, Lorenz
Hartmann, Alina M.
Beder, Thomas
Hänzelmann, Sonja
Kässens, Jan
Bultmann, Miriam
Hoeppner, Marc P.
Franzenburg, Sören
Wittig, Michael
Franke, Andre
Nagel, Inga
Spielmann, Malte
Reimer, Niklas
Busch, Hauke
Schwartz, Stefan
Steffen, Björn
Viardot, Andreas
Döhner, Konstanze
Kondakci, Mustafa
Wulf, Gerald
Wendelin, Knut
Renzelmann, Andrea
Kiani, Alexander
Trautmann, Heiko
Neumann, Martin
Gökbuget, Nicola
Brüggemann, Monika
Baldus, Claudia D.
UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
title UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
title_full UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
title_fullStr UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
title_full_unstemmed UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
title_short UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
title_sort ubtf::atxn7l3 gene fusion defines novel b cell precursor all subtype with cdx2 expression and need for intensified treatment
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162919/
https://www.ncbi.nlm.nih.gov/pubmed/35397658
http://dx.doi.org/10.1038/s41375-022-01557-6
work_keys_str_mv AT bastianlorenz ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT hartmannalinam ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT bederthomas ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT hanzelmannsonja ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT kassensjan ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT bultmannmiriam ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT hoeppnermarcp ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT franzenburgsoren ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT wittigmichael ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT frankeandre ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT nagelinga ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT spielmannmalte ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT reimerniklas ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT buschhauke ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT schwartzstefan ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT steffenbjorn ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT viardotandreas ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT dohnerkonstanze ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT kondakcimustafa ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT wulfgerald ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT wendelinknut ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT renzelmannandrea ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT kianialexander ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT trautmannheiko ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT neumannmartin ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT gokbugetnicola ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT bruggemannmonika ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment
AT baldusclaudiad ubtfatxn7l3genefusiondefinesnovelbcellprecursorallsubtypewithcdx2expressionandneedforintensifiedtreatment